D. Gandara

发表

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

C. Rudin, G. Shapiro, D. Camidge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population-Based Phase I Trial of Irinotecan and Epirubicin

A. Davies, P. Lara, D. Gandara, 2008, American journal of clinical oncology.

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

L. Fehrenbacher, P. Lara, H. West, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)

J. Crowley, J. Jett, H. Lenz, 2008 .

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.

R. Bold, M. Schlieman, S. Virudachalam, 2005, Lung cancer.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Johan Vansteenkiste, G. Scagliotti, Keunchil Park, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.

J. Riess, D. Gandara, Z. Lwin, 2013, Journal of thoracic disease.

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

J. Hainsworth, D. Gandara, P. Hesketh, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

V. Rusch, R. Livingston, D. Gandara, 2001, The Journal of thoracic and cardiovascular surgery.

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

M. Kris, J. Hainsworth, D. Gandara, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.

P. O'dwyer, R. Bukowski, G. Goss, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Association for the Study of Lung Cancer (IASLC)

G. Scagliotti, I. Wistuba, C. Swanton, 2019, Annals of Oncology.

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

S. Peters, J. Mazières, A. Cardona, 2021, Journal for ImmunoTherapy of Cancer.

Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

D. Gandara, R. Dziadziuszko, J. Mazières, 2018, Pneumologie.

Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity.

C. Benz, D. Gandara, S. Monroe, 1987, Cancer treatment reports.

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

R. Govindan, H. Choy, T. Mok, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

D. Gandara, J. Mailliard, R. Navari, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?

L. Young, D. Gandara, L. Xue, 2004, Anti-cancer drugs.

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics

J. Soria, S. Girish, C. Ferté, 2018, Clinical Cancer Research.

Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

P. Hegde, T. Mok, D. Gandara, 2017, Pneumologie.

Phase I study of paclitaxel with oral etoposide in advanced solid tumors.

D. Gandara, D. Lau, D. Campbell, 1996, The cancer journal from Scientific American.

Ondansetron for the prevention of emesis induced by high‐dose cisplatin. A multi‐center dose‐response study

D. Gandara, A. Finn, D. Gandara, 1990, Cancer.

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.

H. Cohen, J. Manola, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

F. Ciardiello, F. Barlesi, M. Ballinger, 2017, Pneumologie.

Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

P. Hegde, F. Hirsch, D. Gandara, 2017, Pneumologie.

Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors

R. Govindan, T. Burns, M. Fakih, 2021, Oral Presentations - Late-Breaking Proffered Abstracts.

A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer

R. Bold, S. Narayan, J. Ryu, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sharing new approaches to translational research in non-small cell lung cancer.

R. Rosell, A. O'brate, M. Tarón, 2000, The oncologist.

S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study.

R. Herbst, F. Hirsch, K. Kelly, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Govindan, H. Choy, T. Mok, 2016, Journal of Clinical Oncology.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, Keunchil Park, F. de Marinis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.